Prof. Dr. Marcus Schittenhelm
Medizinische Onkologie und Hämatologie · Dept. I
A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy
Oct 7, 2024
Clinical Studies - Oct 7, 2024 - Oct 9, 2028
Ongoing
Project leader: Schittenhelm Marcus
Members: Dei Cas Alissa
A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by oneyear mainte-nance in patients with newly diagnosed Acute Myeloid Leu-kemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy
Oct 13, 2021Das Ziel dieser Studie ist es, die Therapie einer akuten myeloischen Leukämie (AML) oder eines myelodysplastischen Syndroms mit erhöhter Anzahl an Leukämiezellen (MDS-EB2) zu verbessern. Wir möchten nun die Wirksamkeit und Sicherheit von Gilteritinib...
Clinical Studies - Oct 13, 2021 - Jul 26, 2028
Ongoing
Project leader: Schittenhelm Marcus
Members: Kehl Jeanine, Quinter Janine
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenancetherapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
Dec 18, 2019IDH1 or IDH2 mutations are each found in about 10% of AML – and specific inhibitors are approved or in development in this indication. The primary objective of this study is to compare event-free survival (EFS) between ivosidenib/enasidenib and pl...
Clinical Studies - Dec 18, 2019 - Jan 31, 2027
Ongoing
Project leader: Schittenhelm Marcus
Members: Kehl Jeanine, Quinter Janine